Freedom to Heal Act of 2025

Access to investigational drugs: The bill allows physicians to directly administer schedule I eligible investigational drugs to eligible patients under the Federal Right to Try law (Sec. 2, paragraph 2).

Streamlined administration through supplemental notifications: Physicians can request additional amounts of an investigational drug through a supplemental notification that is deemed approved after 30 days unless an order to show cause is served (Sec. 2, paragraph 5).

Flexibility for treatment sites: A single registration can cover multiple treatment sites if they are in the same city or county and under the same control, which can simplify the administration of treatment (Sec. 2, paragraph 6).

Administrative burden on physicians: Physicians must submit detailed applications including evidence of registration for other substances, documentation from manufacturers, agreements, proof of state legality, evidence of training, and descriptions of storage sites (Sec. 2, paragraph 3(A)).

Strict limitations on drug possession: Physicians are restricted to possessing only the amounts identified in their initial application or their supplemental notifications (Sec. 2, paragraph 5).

Requirement for Attorney General oversight: The Attorney General has the authority to serve an order to show cause upon applicants, which could delay or impact the registration process (Sec. 2, paragraph 3(B) and paragraph 5(B)(ii)).